Brief: Matinas Biopharma reports Q2 results
11/08/2022 11:40
Aug 11 (Reuters) - Matinas BioPharma Holdings Inc MTNB.A :
* MATINAS BIOPHARMA REPORTS SECOND QUARTER 2022 FINANCIAL
RESULTS
AND HIGHLIGHTS RECENT PROGRESS
* FOR Q2 , NET LOSS WAS $5.9 MILLION, OR A NET LOSS OF $0.03
PER
SHARE (BASIC AND DILUTED)
Source text for Eikon: ID:nGNX2qQqsr
Further company coverage: MTNB.A
Recent news on Matinas BioPharma Holdings
See all newsBrief: GH Power Signs Multi-Year Hydrogen Offtake Agreement With Change Energy For Hamilton Facility Output
Brief: Gh Power And Tkms Continue To Explore Clean Energy Collaboration In Support Of Canada’S Future Patrol Submarine Project
Brief: Matinas Biopharma - Btig Terminates Sales Agreement With Matinas Biopharma Holdings, Effective Immediately On July 23, 2026 - SEC Filing
Brief: Matinas Biopharma Receives Notice Of Non-Compliance With NYSE American Continued Listing Standards And Acceptance Of Plan To Regain Compliance
Brief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing